Corporate Update
Biocon sees larger licensing income from pharma
Biocon sees larger licensing income from pharma
![]()
By eHealth Network - 27 January 2012
Biocon , India’s top-listed biotechnology company, expects to generate larger licensing income from pharmaceuticals business, its Chairman and Managing Director said.
The Bangalore-based drugmaker earlier said consolidated net profit fell 15.8 percent in December quarter, while revenue rose 3 percent. The sales growth in the fiscal third quarter ended December 31 was flat on lower licensing income.The company said, licensing fees and income dropped to 292 million rupees in October-December from 768 million rupees a year earlier.
Biocons presence straddles four main therapeutic areas Diabetology, Cardiology, Nephrology and Oncology even as it plans to introduce two new divisions, Comprehensive Care, and Immunotherapy, this year.
Like
Dislike
Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.
